Stock comparison
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ANIP
ANI Pharmaceuticals
Market cap
$1.88B
Sector
Healthcare
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
| Strategy | ANIP | HAE | Winner |
|---|---|---|---|
| Warren Buffett | 53C | 70B | HAE |
| Benjamin Graham | 59D | 85A | HAE |
| Philip Fisher | 58C | 60C | HAE |
| Peter Lynch | 71C | 54C | ANIP |
| Joel Greenblatt | 44D | 31F | ANIP |
| Charlie Munger | 47D | 54D | HAE |
| Terry Smith | 50D | 55D | HAE |
| Metric | ANIP | HAE |
|---|---|---|
| Market cap | $1.88B | $2.98B |
| P/E (TTM) | 18.5x | 24.8x |
| EV/EBIT | 22.4x | 14.1x |
| ROIC (TTM) | 8.17% | 8.37% |
| Gross margin | 65.94% | 55.74% |
| Net margin | 9.71% | 7.29% |
| Revenue CAGR 5y | 42.18% | 7.65% |
| EPS CAGR 5y | - | 24.62% |
| Debt / Equity | 0.6x | 1.5x |
| Dividend yield | 0.0% | 0.0% |
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ANIP leads on
HAE leads on
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.